Vanguard Capital Management
PALI icon

Vanguard Capital Management’s Palisade Bio PALI Stock Holding History

Vanguard Capital Management’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.6M Buy
1,722,817
+293,509
+21% +$578K ﹤0.01% 3229
2026
Q1 		$2.5M Buy
+1,429,308
New +$2.6M ﹤0.01% 3289

Other funds holding PALI

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management's PALI Position: Q2 2026 in Review

Vanguard Capital Management increased its Palisade Bio (PALI) stake by 21% in Q2 2026, buying an estimated $578K and bringing the position to 1,722,817 shares worth $3.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3229.

Vanguard Capital Management first reported a position in PALI in Q1 2026 and has held it in 2 quarters since. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

  • Vanguard Capital Management held 1,722,817 shares of Palisade Bio worth $3.6M as of Q2 2026.
  • Vanguard Capital Management bought 293,509 Palisade Bio shares in Q2 2026, an estimated $578K.
  • Palisade Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3229 holding.
  • Vanguard Capital Management first reported a position in Palisade Bio in Q1 2026 and has held it in 2 quarters since.
  • 124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.